The prevalence of KRAS mutations in CRC, which are mutually exclusive from BRAF mutations [39], also underscores the need to identify diverse means of targeting the RAS/RAF/MEK/ERK signaling cascade [38]. This evidence concerns the gene RAF1 and colorectal carcinoma.